IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-18.72%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$161M
AUM Growth
+$161M
(-23%)
Cap. Flow
-$15.6M
Cap. Flow
% of AUM
-9.66%
Top 10 Holdings %
Top 10 Hldgs %
56.91%
Holding
57
New
6
Increased
7
Reduced
18
Closed
12
Top Buys
| 1 |
Gilead Sciences
GILD
|
$6.04M |
| 2 |
Neurocrine Biosciences
NBIX
|
$5.06M |
| 3 |
Biogen
BIIB
|
$4.06M |
| 4 |
Amgen
AMGN
|
$3.67M |
| 5 |
RDUS
Radius Health, Inc.
RDUS
|
$3.18M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$8.64M |
| 2 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$5.67M |
| 3 |
Puma Biotechnology
PBYI
|
$5.07M |
| 4 |
Illumina
ILMN
|
$4.24M |
| 5 |
SPPI
Spectrum Pharmaceuticals Inc
SPPI
|
$3.86M |
Sector Composition
| 1 | Healthcare | 95.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $12.7M | 7.88% | 254,500 +54,500 | +27% | +$2.72M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $11.7M | 7.28% | 90,122 +22,400 | +33% | +$2.91M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $11.4M | 7.05% | 225,522 -28,000 | -11% | -$1.41M |
|
|
4
Gilead Sciences
GILD
$140B
| $10.5M | 6.5% | 213,284 +123,000 | +136% | +$6.04M |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.19M | 5.7% | 31,330 | – | – |
|
6
Exelixis
EXEL
$10.1B
| $9.11M | 5.65% | 589,534 -115,000 | -16% | -$1.78M |
|
|
7
Illumina
ILMN
$15.8B
| $7.92M | 4.91% | 33,600 -18,000 | -35% | -$4.24M |
|
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $7.05M | 4.38% | 125,800 +90,300 | +254% | +$5.06M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.18M | 3.83% | 92,284 -5,000 | -5% | -$335K |
|
10
Ligand Pharmaceuticals
LGND
$3.15B
| $6M | 3.72% | 56,300 +21,300 | +61% | +$2.27M |
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $5.63M | 3.5% | 73,641 -8,000 | -10% | -$612K |
|
12
KalVista Pharmaceuticals
KALV
$678M
| $4.95M | 3.07% | 319,444 -2,992 | -0.9% | -$46.4K |
|
13
Halozyme
HALO
$8.56B
| $4.58M | 2.84% | 398,633 -30,000 | -7% | -$345K |
|
|
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
| $4.37M | 2.71% | 585,930 | – | – |
|
|
15
Biogen
BIIB
$19.4B
| $4.06M | 2.52% | +17,200 | New | +$4.06M |
|
|
16
Amgen
AMGN
$155B
| $3.67M | 2.28% | +24,000 | New | +$3.67M |
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.58M | 2.22% | 282,065 +217,065 | +334% | +$2.75M |
|
|
RDUS
18
DELISTED
Radius Health, Inc.
RDUS
| $3.42M | 2.12% | 264,211 +245,412 | +1,305% | +$3.18M |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $3.42M | 2.12% | 25,000 | – | – |
|
|
ABMD
20
DELISTED
Abiomed Inc
ABMD
| $2.99M | 1.85% | 11,700 -1,500 | -11% | -$383K |
|
|
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
| $2.66M | 1.65% | 93,000 -17,000 | -15% | -$486K |
|
22
Enanta Pharmaceuticals
ENTA
$180M
| $2.39M | 1.48% | +43,000 | New | +$2.39M |
|
|
XENT
23
DELISTED
Intersect ENT, Inc
XENT
| $2.12M | 1.32% | 96,000 -16,000 | -14% | -$354K |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.94M | 1.2% | 33,800 -19,000 | -36% | -$1.09M |
|
|
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.89M | 1.17% | 42,500 | – | – |
|